Research Paper | Oncology Science | Egypt | Volume 6 Issue 9, September 2017
Which is More Effective; Docetaxel, Doxorubicin and Cyclophosphamide Or 5-Fluorouracil, Doxorubicin and Cyclophosphamide in Adjuvant Treatment of Early Stage Node Positive Breast Cancer?
Rehab F Mohamed, Abeer F Amin, Mohamed Alaa Elden Hassan Mohamed, Rania A Abdelhamid
Abstract: Background The aim of this study is to compare the efficacy and the safety of docetaxel, doxorubicin and cyclophosphamide (TAC) with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) as adjuvant treatment for early stage node positive breast cancer patients. Methods Sixty patients with pathologically confirmed early stage node-positive breast cancer were randomly assigned to receive six cycles of eitherdocetaxel (75mg/m), doxorubicin (50mg/m) and cyclophosphamide (500mg/m) every three weeks or 5-fluorouracil (500mg/m), doxorubicin (50mg/m) and cyclophosphamide (500mg/m) every three weeks as adjuvant treatment. The two chemotherapy regimens were compared in term of disease free survival (DFS) and overall survival (OS). Results At a median follow-up of 30 month, the median estimated rate of DFS for patients in the TAC group was 24 month compared to 20 month for patients in the FAC group which was statistically significant (95 % confidence interval [CI], 0.49 to 7.17, P <0.04). In terms of OS, no significant difference between the two treatment groups, the median estimated rate of OS in the TAC arm was 25 month compared to 24 month in the FAC arm ( CI, 2.84 to 5.27, P= 0.522). No significant difference in DFS as regardingthe prognostic factors as number of involved axillary lymph nodes (p=0.485), menopausal status (P=0.684), hormone-receptor status (P=0.795) and HER2/neustatus (P=0.509). The incidence of grade 2-3 anemia was higher in the TAC group than in the FAC group (23.3 % versus 13.3 %, P<0.04). As regarding neutropenia, it occurred more frequently in the TAC group (13.3 % versus 6.7 %, P<0.04). The incidence of grade 3 febrile neutropenia in the TAC group was 10 % versus 3.3 % in the FAC group (P=0.372). Conclusion Incorporation of docetaxel in the adjuvant treatment of early node-positive breast cancer patients improves the DFS with tolerable toxicity compared to FAC regimen. However, further follow-up is needed to demonstrate its effect on the OS.
Keywords: TAC/FAC, adjuvant, node-positive, breast cancer, survival
Edition: Volume 6 Issue 9, September 2017,
Pages: 59 - 64
How to Cite this Article?
Rehab F Mohamed, Abeer F Amin, Mohamed Alaa Elden Hassan Mohamed, Rania A Abdelhamid, "Which is More Effective; Docetaxel, Doxorubicin and Cyclophosphamide Or 5-Fluorouracil, Doxorubicin and Cyclophosphamide in Adjuvant Treatment of Early Stage Node Positive Breast Cancer?", International Journal of Science and Research (IJSR), https://www.ijsr.net/get_abstract.php?paper_id=ART20176407, Volume 6 Issue 9, September 2017, 59 - 64
How to Share this Article?
Similar Articles with Keyword 'adjuvant'
Regarding Clinical Response, Neoadjuvant Chemoradiation is More Effective than Neoadjuvant Radiation alone in the Treatment of Advanced Stage (Stage II and III) of Rectal Carcinoma
Dr. Md. Zillur Rahman Bhuyain, Dr. Sharif Ahmed, Dr. Sadia Sharmin, Dr. Mamun OR Rasheed
Definitive Radiotherapy for Vaginal Angiomyofibroblastoma
Dr Rashmi S, Dr Vaishnavi P Reddy, Dr Kiran Kumar B R, Dr Sanjeet K Mandal
Similar Articles with Keyword 'breast cancer'
Finding the Correlation of Thyroid Disorders and Menopausal Relationship with Benign Breast Diseases
Harinandini Appam, Ushasree Adepu, Brahmani Bachu, Avinassh Tippani
In-Vitro Assessment of Anticancer Potential of Lapatinab and Bee Venom against Breast (MCF-7) and Prostate (PC-3) Cancer Cell Lines: In-Vitro Study
N. Karem, A. Fahmy
Similar Articles with Keyword 'survival'
Prognostic Significance of Ratio of Metastatic Lymph Nodes (MLNR) to Total Lymph Nodes Harvested in Squamous Cell Carcinoma of Esophagus
Vikas Sharma, S Krishnamurthy
P16 Expression Independent of Human Papilloma Virus in Egyptian Patients with Head and Neck Squamous Cell Carcinoma: A Retrospective Study
Dina RD. Ibrahim, Reham M. Faheim, Mohamed R. Kelany, Nahla M. Awad, Hala M. El-Sallaly, Nashwa N. El-Khazragy